Thrombin has many biological properties similar to those of growth factors. In a previous study, we showed that thrombin improves healing of the rat tendo Achillis. Low molecular weight heparin (LMWH) inhibits the activity and the generation of thrombin. We therefore considered that LMWH at a thromboprophylactic dose might inhibit tendon repair.
Thrombin has many biological properties similar to those of growth factors. In a previous study, we showed that thrombin improves healing of the rat tendo Achillis. Low molecular weight heparin (LMWH) inhibits the activity and the generation of thrombin. We therefore considered that LMWH at a thromboprophylactic dose might inhibit tendon repair.
Transection of the tendo Achillis was carried out in 86 rats and the healing tested mechanically. Low molecular weight heparin (dalateparin) was either injected a few minutes before the operation and then given continuously with an osmotic mini pump for seven days, or given as one injection before the operation. In another experiment ,we gave LMWH or a placebo by injection twice daily. The anti-factor Xa activity was analysed.
Continuous treatment with LMWH impaired tendon healing. After seven days, this treatment caused a 33% reduction in force at failure, a 20% reduction in stiffness and a 67% reduction in energy uptake. However, if injected twice daily, LMWH had no effect on tendon healing. Anti-factor Xa activity was increased by LMWH treatment, but was normal between intermittent injections. Low molecular weight heparin delays tendon repair if given continuously, but not if injected intermittently, probably because the anti-factor Xa activity between injections returns to normal, allowing sufficient thrombin stimulation for repair. These findings indicate the need for caution in the assessment of long-acting thrombin and factor Xa inhibitors.
Most orthopaedic surgery involves soft collagenous tissues, and their post-operative healing influences rehabilitation and the long-term results. It is therefore important to know whether drugs given to these patients can delay the healing of soft tissue.
Thrombin is a proteolytic enzyme that converts several proteins from an inactive pro-form to an active state. Its most important effects are to activate platelets and to convert soluble fibrinogen to insoluble fibrin. Many thromboprophylactic treatments aim to reduce thrombin activity. Thrombin itself is also activated by proteolysis of prothrombin by factor Xa, as a result of the coagulation cascade. Factor Xa activity is therefore the target of most thromboprophylactic drugs.
Thrombin has many biological properties similar to those of growth factors. It activates or releases matrix-bound mitogenic factors by catalysis, and can also activate cell surface receptors. It is also able to stimulate mitogenic and other cell surface receptors independent of its enzymatic function.
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A non-enzymatic thrombin analogue has been shown to improve the repair of dermal wounds and fractures by increasing several components of the healing cascade, leading, among other things, to increased vascularisation. 2 In a previous study 3 we showed that locallyinjected bovine thrombin improves the healing of the transected tendo Achillis in the rat. Considering that thrombin is a natural part of the repair process, and that exogenous thrombin accelerates it, it is conceivable that a reduction in thrombin activity should have an adverse effect. Low molecular weight heparins (LMWHs) inhibit coagulation factor Xa and hence the generation of thrombin, but except for the pentasacharide fondaparinux they also affect thrombin directly to a variable degree. We therefore considered that LMWH might inhibit tendon repair and tested this in a rat study. Because we needed to give LMWH in a dose having some relevance to the human situation, we measured the activity of anti-factor Xa to ascertain that we had reached a thromboprophylactic level in the animals. In order to exclude any effects that were the consequences of a possible increase in bleeding, continuous LMWH treatment was compared with controls that had received preoperative LMWH treatment only. Having established that continuous LMWH treatment impaired tendon healing, we tested a second hypothesis that daily periods of no inhibition of coagulation, as evidenced by normalised factor Xa activity, would allow sufficient stimulation by thrombin to permit normal repair.
Materials and Methods
We used 86 Sprague-Dawley rats. Initially, 20 rats were randomised into two groups of ten: one for continuous treatment with LMWH, the other as a control (experiment 1). The results were evaluated at seven days and LMWH treatment showed impaired tendon healing.
We then used a further 30 rats divided into three groups. One received continuous treatment, the second a single injection of LMWH during the operation, and the third group was left untreated (experiment 2). Continuous treatment with LMWH again showed impaired healing of the tendon. To mimic a clinical dosing regimen, 20 rats were then randomised to receive LMWH or saline as subcutaneous injections twice daily (experiment 3). There was no difference between treated and control groups. Finally, antifactor Xa was analysed in 16 rats (experiment 4). Blood was taken two and 12 hours after the injection of LMWH and from a control group (Table I) . Operative procedure and treatment. The rats were anaesthetised with 5% isoflurane gas (Forene, Abbot Scandinavia, Solna, Sweden) initially in an induction chamber and then with 3.5% isoflurane via a mask. The skin on the right hind limb was shaved. A 5 mg intramuscular injection of tetracycline (Engemycin; Intervet, Boxmeer, The Netherlands) and analgesia in the form of 0.015 mg buprenorphine (Temgesic; Schering-Plough, Brussels, Belgium) were given pre-operatively. The animal was placed prone on a warm pad (38.2˚C) and the right hind leg was stretched backwards and washed with chlorhexidine (chlorhexidine digluconate 5 g, ethanol 600 g, sterile water). A transverse incision 3 mm long was made in the skin lateral to the right tendo Achillis. The surrounding fascia was opened and the tendon complex exposed. Approximately 7 mm of the plantaris tendon was then removed to simplify force measurements at the end of the experiment. Subsequently, the tendon was cut transversely 1.5 mm and 4.5 mm proximal to the calcaneal insertion, and the segment between was removed. The tendon was left unsutured with a gap between the stumps and the skin was sutured. After the operation, the animals were placed in clean cages under a heating lamp at constant temperature of 30˚C until they had woken up completely and mobilised.
Subcutaneous injections consisted of 40 international units (IU) (200 IU/kg/24h) dalteparin sodium (Fragmin; Pfizer AB, Sollentuna, Sweden) given by osmotic mini pumps (model No. 2001, pumping rate 1.0 ml/h; Alzet, B&K Universal, Sollentuna, Sweden) with 280 IU Fragmin, implanted subcutaneously between the scapulae. Thus, 1.6 IU were delivered per hour, which corresponds to 7 IU/kg/h.
The rats were divided into experimental and control groups for treatment chosen by lottery by an assistant before the operation. The surgeon (OV) was not aware of the intended treatment until after the surgery was completed and it was time to insert the mini pump. Evaluation. After seven days, the rats were killed with CO 2 gas. The tendon with the attached calcaneal bone was dissected free from other tissues and removed. The sagittal and transverse diameters were measured with a digital calliper. For clamping, the muscle was carefully scraped off the tendon substance by blunt dissection, to produce a fan of tendon fibres which was then sandwiched between fine sandpaper in metal clamps. The calcaneum was screwed in a custom-made clamp in 30d orsiflexion relative to the direction of traction. Finally, the clamps were attached to a materials testing machine (100R, DDL Inc., Eden Prairie, Minnesota), and the tendon pulled at a constant speed of 0.1 mm/s until failure. The mechanical parameters measured were the force at failure, the stiffness, and the energy uptake at 10% drop of the curve. Stress and transverse area were calculated. Blood samples were collected by heart puncture in anaesthetised rats, using 1.4 ml coagulation syringes (9NC/1.4 ml; S-Monovette, Sarstedt, Germany).
The study had ethics committee approval and was conducted in accordance with Swedish law for animal experimentation.
Measurement of anti-factor Xa activity in the blood.
Measurement of anti-Xa was carried out on citrated plasma using the reagent Coamtic Heparin purchased from Haemochrom Diagnostic (Mölndal, Sweden) on an automated coagulation analyser (ACL Futura, Milan, Italy) according to the manufacturer's instructions. Statistical analysis. The force at failure was chosen as the main outcome variable. Statistical analysis was performed using StatView for Windows version 5.0.1 (SAS Institute, Cary, North Carolina). Experiments with two groups were evaluated with Student's t -test and three groups were compared by analysis of variance (ANOVA) followed by Fisher's probability of least significant difference (PLSD) post hoc test. A p-value of < 0.05 was considered significant.
Results
One rat in experiment 1 was excluded because of infection. Otherwise, all the rats were included in the analysis. All the specimens ruptured in the mid-substance where the tendon callus had formed in the gap.
In experiment 1, comparing continuous treatment with untreated controls, LMWH caused a 27% reduction in force at failure (Table II) . Stiffness and energy uptake were also reduced. The transverse area tended to be reduced as well, but this was not statistically significant.
In experiment 2, comparing continuous treatment with untreated controls and controls with a pre-operative dose of LMWH, the two controls were almost identical. Continuous LMWH caused a 25% reduction in force at failure compared to untreated controls. Stiffness and energy were reduced to a similar degree as in experiment 1, but without statistical significance. The transverse area was reduced (Table III) . We also pooled the two control groups, untreated and with a single pre-operative dose, to make a two-group comparison. This led to a statistically significant difference in all comparisons between continuous treatment and combined controls (t-test; p-value for force 0.008, stiffness 0.03, energy 0.03, area 0.0001 and stress 0.002).
In experiment 3, comparing injections twice daily with controls, no significant differences were seen (Table IV) .
In experiment 4, we found that the injection regimen in experiment 3 led to a significant increase in anti-factor Xa activity by two hours after the injection, but that the activity had returned to normal after 12 hours (Table V) . Thus, we had mimicked the human situation in which the antifactor Xa activity has time to normalise between injections.
Discussion
These results confirm that continuous treatment with LMWH has a detrimental effect on tendon repair. The callus bridging the gap in the tendon became thinner, which explains the reduced force at failure. The stress at failure, a material property, was unchanged or even improved. This suggests that most of the detrimental effect of the treatment was related to proliferation and growth of the early callus, whereas tissue differentiation, and probably the ability to respond to mechanical stimulation of differ- entiation, was undisturbed. The results are also consistent with those of our previous study, where a single thrombin injection six hours after the operation had an opposite effect to the inhibition of thrombin in the present study as it led to a 10% increase in strength after 14 days (p = 0.003) and a non-significant increase in the transverse area. 3 The model differs from ruptures of the tendo Achillis tendon in humans with regard to species, size and treatment. It may, however, provide some general information about the healing of collagenous tissues. Reduced growth of the early callus due to LMWH is consistent with a reduction in the mitogenic or proliferative signalling of thrombin, because of a direct inhibition of thrombin and inhibition of thrombin formation by inhibition of factor Xa. Dalteparin inhibits both prothrombin and factor Xa, but the specific activity towards Xa is twice that towards thrombin. 4 The present study was not designed to elucidate the relative importance of these two mechanisms. Because pre-operative treatment with LMWH did not influence the results, it seems clear that the effects of LMWH are unrelated to any effects on peri-operative bleeding, but came in hours later, when the inflammatory and regenerative processes had begun. The continuous dose of 7 IU/kg/h used is relevant as it is in between the doses of 5 IU/Kg/h and 10 IU/kg/h used by Eriksson et al, 4 which were effective in reducing the weight of thrombus in a rat model of vena cava thrombosis.
Our results would be likely to surprise the clinician if we did not also have the results from intermittent treatment. Clinically, thromboprophylaxis is given intermittently. It is effective against thrombus formation, although anti-factor Xa activity is regularly normalised between injections. Anti-factor Xa activity is not directly correlated to the antithrombotic effect. In a model of experimental venous thrombosis in the rat, the half-life for the antithrombotic effect was significantly longer than for anti-Xa and anti-IIa activities. 5 The dichotomy between the antithrombotic effect and growth stimulation may be related to the difference between proteolytic activity and direct receptor stimulation by thrombin. 2 Periods of mitogenic stimulation are enough to trigger the processes necessary for the early formation of tendon callus or granuloma, whereas periods of reduced fibrin formation might be sufficient to reduce thrombus formation or growth. This is a cause for concern in new drugs which are being developed to have a continuous anti-Xa effect with once-weekly doses. It is possible that they will have a detrimental effect as with continuous dosing in our study, although in contrast to dalteparin, 6 fondaparinux does not inhibit human osteoblast proliferation in vitro .
We do not know how our findings with the tendo Achillis in the rat relate to human tendon or other collagenous soft tissues, but the finding of a possible adverse effect should be recognised in the clinical evaluation of thromboprophylactic drugs. 
